Prospectively Defining Secondary Progressive MS
Hovedforsker: Fred Lublin
Primær instution: Icahn School of Medicine; Mount Sinai, NY
More accurate and earlier determination of the onset of secondary progressive MS is needed compared to current clinical determination, which is only made after an individual has entered the progressive phase. The project aims to identify a reliable predictor of secondary progressions, and will bring together an international consortium of MS Centers who have collected information on patients with MS over a long period of time and together develop strategies analyzing the information that could lead to new biomarkers. By studying clinical and MRI data on patients carefully followed for many years, early and reliable markers of transition into secondary transition will be developed, enabling better treatment strategy for this phase of MS.